目的 探讨骨疏康胶囊联合地舒单抗注射液治疗绝经后骨质疏松症的临床疗效。方法 选择2023年6月—2025年5月在秦皇岛市第二医院就诊的绝经后骨质疏松症患者共130例，患者以随机数字表法分为对照组和治疗组，各65例。对照组肌肉注射地舒单抗注射液，120 mg/次，6个月治疗1次。治疗组在对照组基础上口服骨疏康胶囊，4粒/次，2次/d。两组的疗程为6个月。比较两组的治疗效果、疼痛程度、绝经期症状、骨密度和血清炎症指标。结果 对照组的总有效率为73.85%，治疗组的总有效率为87.69%，组间差异显著（P＜0.05）。治疗后，两组的数字疼痛强度量表（NRS）、更年期综合征评分量表（Kupperman）评分显著降低（P＜0.05）；治疗组治疗后的NRS、Kupperman评分低于对照组（P＜0.05）。治疗后，两组腰椎、股骨颈、桡尺骨的骨密度均明显升高（P＜0.05）；治疗组治疗后的腰椎、股骨颈、桡尺骨的骨密度高于对照组（P＜0.05）。两组治疗后的系统性免疫炎症指数（SII）均明显降低，血清白细胞介素-33（IL-33）、胰岛素样生长因子-1（IGF-1）水平均明显升高（P＜0.05）；治疗组治疗后的SII低于对照组，血清IL-33、IGF-1水平均高于对照组（P＜0.05）。结论 骨疏康胶囊联合地舒单抗注射液可提高绝经后骨质疏松症的治疗效果，进一步减轻疼痛程度和绝经期症状，提高骨密度，降低炎症反应。

Objective To investigate the clinical efficacy of Gushukang Capsules combined with Denosumab Injection in treatment of postmenopausal osteoporosis. Methods 130 Patients with postmenopausal osteoporosis who received treatment at The Second Hospital of Qinhuangdao from June 2023 to May 2025 were divided into control group and treatment group using a random number table method, with 65 patients in each group. The control group received iv of Denosumab Injection, 120 mg/time, once every 6 months for treatment. The treatment group took oral Gushukang Capsules on the basis of the control group, 4 capsules/time, twice daily. The treatment course for two groups was 6 months. The treatment efficacy, severity of pain, menopausal symptoms, bone density, and serum inflammatory indicators were compared between two groups. Results The total effective rate of the control group was 73.85%, while the total effective rate of the treatment group was 87.69%, with significant differences between two groups (P < 0.05). After treatment, the digital pain intensity scale (NRS) and menopausal syndrome score scale (Kuperman) scores of two groups significantly decreased (P < 0.05). The NRS and Kuperman scores of the treatment group were lower than those of the control group after treatment (P < 0.05). After treatment, the bone density of the lumbar spine, femoral neck, radius and ulna in two groups significantly increased (P < 0.05), and the bone density of the lumbar spine, femoral neck, radius and ulna in the treatment group was higher than that in the control group (P < 0.05). The systemic immune inflammatory index (SII) was significantly reduced in two groups after treatment, but the serum levels of interleukin-33 (IL-33) and insulin-like growth factor-1 (IGF-1) were significantly increased (P < 0.05). The SII level in the treatment group was lower than that in the control group after treatment, but the serum levels of IL-33 and IGF-1 were higher than those in the control group (P < 0.05). Conclusion Gushukang Capsules combined with Denosumab Injection can provide therapeutic effects for postmenopausal osteoporosis, further reducing pain intensity and menopausal symptoms, improving bone density, reducing inflammatory responses.

R977

秦皇岛市科学技术研究与发展计划项目（201703A059）